GBC 1

KEYNOTE SPEECH & PLENARY SESSION 기조강연 & 특별강연

Keynote Speech / 기조연설
People-centered Bioeconomy / 사람 중심, 바이오경제

The 4th Industrial Revolution and Convergence of BT & IT
4차 산업혁명, BT와 IT의 융합을 위하여
Byung-Gyu Chang (Chairman, Presidential Committee on the Fourth Industrial)

Access to quality assured medicines and vaccines - what next?
고품질 의약품과 백신에 대한 접근 가능성, 그리고 그 이후의 전망
Mariângela Simão (Assistant Director-General, WHO)

Gene Therapy Efficient Drug Development
유전자 치료 분야에서의 효과적인 약 개발
Wilson W. Bryan (US FDA)

"Health for AllChanges Brought by mAb Biosimilar"
인류의 건강과 헬스케어 산업 – 세계 최초 항체 바이오시밀러가 불러온 변화
Jung Jin SEO (Chairman, Celltrion Group)

Plenary Session 특별강연

The Future of Health with AI and Blockchain Technology
AI와 블록체인 기술이 만드는 보건 분야의 미래
Annette Hicks (Senior Health Advisor, Watson Health, IBM)

USP Perspective in Biologics
생물학적 제제에 대한 USP의 관점
Ronald Piervincenzi (CEO, USP)

Precision Healthcare with Personal Genome Information
개인 유전체정보기반 정밀의료
Woongyang Park (Director, Samsung Medical Center)

Advancing the BioEconomy through Human Data Science
휴먼 데이터 사이언스를 통해 발전하는 바이오 경제
Murray Aitken (Executive Director, IQVIA)

Regulatory trends for innovation in biopharmaceutical manufacturing technologies
바이오의약품 제조 기술 혁신을 위한 규제 동향
Janmeet Anant (Senior Regulatory Consultant, Merck)

Successful planning and implementation for alliances: the winning strategy!
성공적인 바이오의약품 개발 전략, 협력 및 실행
Stefan Gluck (Vice President, Celgene Corporation)

[GBC 1] KEYNOTE SPEECH & PLENARY SESSION

Byung-Gyu Chang

Chairman, Presidential Committee on the Fourth Industrial

Chairperson, Presidential Committee on the Fourth Industrial Revolution (PCFIR)
Chairperson, PCFIR (September 2017 to present)
Advisor and CEO, BonAngels Venture Partners (2008 to present)
Chairperson, Bluehole corp. (2007 to present)
Co-founder, 1noon.com
Co-founder, Neowiz

Before his appointment as chairperson of the PCFIR, Byung-Gyu Chang made a name for himself as one of the leading startup entrepreneurs and investors in Korea. He continues to chair the board of directors at Bluehole, a company he co-founded in 2007, and also serves as an advisor for BonAngels Venture Partners, an early-stage venture capital company that he co-founded with two partners in 2008. In 2006, Chang sold his search engine startup, 1noon.com, to NHN. Prior to that, he co-founded and ran Neowiz in 1996. In 1991, Chang entered the Korea Advanced Institute of Science and Technology (KAIST), where he majored in computer science.

The 4th Industrial Revolution and Convergence of BT & IT

Convergence of BT and IT is considered something inevitable in the era of the 4th industrial revolution, when various technologies are combined to create more values. Many IT businesses like Apple, Google and IBM are already in the game, actively challenging the bio sector.

Korea has high potentials in the bio sector, with its pool of highly advanced human resources, massive amount of data accumulated from nationwide coverage of the national health insurance system and its competitive edge in the clinical sector. In order for Korea to use the potentials as a foothold and take a leap forward to become a powerful country in the bio sector, active collaboration between the IT industry and other industries is a must.

In this regard, the Presidential Committee on the Fourth Industrial Revolution of Korea is making efforts to create a new healthcare ecosystem based on the BT and IT convergence as well as provide a floor for social consensus, where issues and disputes over bio regulations are discussed and settled.

[GBC 1] KEYNOTE SPEECH & PLENARY SESSION

Mariângela Simão
Assistant Director-General, WHO

Mariângela Simão joined WHO in November 2017, as part of Dr Tedros Adhanom Ghebreyesus leadership team.

She previously worked for UNAIDS since September 2010 and prior to that, she worked for the Ministry of Health in Brazil as the Director of the Sexually Transmitted Diseases, HIV/ AIDS and Viral Hepatitis department.

She worked in the Brazilian public health system since 1982, from the primary health care level to a series of managerial positions throughout the years. As a public health professional, at municipal, state and national levels, she played an active role in the decentralization of the national health system, acquiring an extensive experience in health system strengthening. She has also served on the boards of a number of organizations and government committees related to public health and HIV.

Heading the National Sexually Transmitted Diseases/HIV/AIDS Department (including Viral Hepatitis from 2009), she had the responsibility of overseeing and implementing the national Sexually Transmitted Diseases/AIDS/Viral Hepatitis policies, including universal and free of charge access to treatment, care and comprehensive prevention programs.

Dr. Simão attended medical school in Brazil, with degrees in Paediatrics and Public Health, and a MSc in Mother and Child Health in the UK.

Access to quality assured medicines and vaccines – what next?

Framed on the global commitments regarding access to medicines, vaccines and health products both in the SGD Agenda 2030 and WHO's new strategy – Global Program of Work 13. SDG 3 "ensuring healthy lives and wellbeing for al at all ages", including its 3.8 target was adopted by all member states at the UN General Assembly. Member states are accountable to deliver on them.

Access is analyzed in terms of 4 dimensions: affordability, effectiveness, quality assurance and safety.

On affordability several examples are used, which affect both developing and developed countries – notably the need to reduce out of pocket expenses for medicines and health products and the differential prices that are paid by a diverse number of countries on the same products.

On effectiveness, emphasis is given to make the best use of WHO's essential medicines list, with several examples where new products at high prices do not necessarily impact on patients overall wellbeing and survival. An interesting product of EML is the AWARE of antibiotics, which provides a tool to better inform regulators and prescribers about the antibiotic as part of the framing of antimicrobial resistance – AMR.

On quality assurance, two mains aspects are analyzed – WHO's work with regulatory system strengthening, including the future issue of a WHO listed authorities in replacement of the current stringent list of authorities, For this the process using a global benchmarking tool to best guide the work of NRAs is undergoing with some examples of success.

Lastly, an analysis of safety, from the perspective of the data available on standard and falsified medicines provides some good examples of how data can improve visibility of problems that are common in both developed and developing worlds to different extents, but that require a very collaborative approach to be solved.

[GBC 1] KEYNOTE SPEECH & PLENARY SESSION

Wilson W. Bryan
US FDA

EDUCATION

University of South Carolina	1974 - 1978
University of Chicago, Pritzker School of Medicine	1978 - 1982

HONORS

Trephined Cranium Award for Neurology Resident Teaching	
The University of Texas Southwestern Medical Center at Dallas	1990, 1992, 1993, 1999

ADMINISTRATIVE EXPERIENCEW

The University of Texas Southwestern Medical Center at Dallas:	
Director, Transitional Year Residency Program	1993-1997
Vice Chairman, Department of Neurology	1998-2000

PUBLICATIONS

Refereed Publications (58):

Fleckenstein JL, Weatherall PT, Bertocci LA, Ezaki M, Haller RG, Greenlee RG Jr, Bryan WW, Peshock RM. Locomotor system assessment by muscle magnetic resonance imaging. Magn Reson Quar 1991; 7: 79-103.

Ringel SP, Murphy JR, Alderson MK, Bryan W, England JD, Miller RG, Petajan JH, Smith SA, Roelofs RI, Ziter F, Lee MY, Brinkmann JR, Almada A, Gappmaier E, Graves J, Herbelin L, Mendoza M, Mylar D, Smith P, Yu P. The natural history of amyotrophic lateral sclerosis. Neurology 1993; 43: 1316-1322.

Katz JS, Wolfe GI, Burns DK, Bryan WW, Fleckenstein JL, Barohn RJ. Isolated neck extensor myopathy: a common cause of dropped head syndrome. Neurology 1996;46: 917-921.

Katz JS, Wolfe GI, Bryan WW, Jackson CE, Amato AA, Barohn RJ. Electrophysiologic findings in multifocal motor neuropathy. Neurology 1997;48: 700-707.

Bryan WW, Hoagland RJ, Murphy J, Armon C, Barohn RJ, Goodpasture JC, Miller RG, Parry GJ, Petajan JH, Ross MA, Stromatt SC, and the rhCNTF ALS Study Group. Can We Eliminate Placebo in ALS Clinical Trials? Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders 2003; 4:11-15.

Sridhar G, Tian F, Forshee R, Kulldorff M, Selvam N, Sutherland A, Bryan W, Barone S, Xu L, Izurieta HS. Evaluation of optic neuritis following human papillomavirus vaccination. Human Vaccines and Immunotherapeutics 2017; 13:7, 1705-1713.

ABSTRACTS (81)

Bryan W, Lewis SF, Bertocci L, Gunder M, Ayyad K, Gustafson P, Haller RG. Muscle lactate dehydrogenase deficiency: a disorder of anaerobic glycogenolysis associated with exertional myoglobinuria. Neurology 1990;41(suppl 1):203.

Miller RG, Bryan WW, Dietz M, Munsat TL, Petajan JH, Smith SA. Safety, tolerability, and pharmacokinetics of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis. Ann Neurol 1993;34(2):P241.

BOOK CHAPTER

Katz JS, Bryan WW, Barohn RJ. Infectious and granulomatous neuropathy. In: Samuels MA, Feske S (eds.). Office Practice of Neurology, Churchill Livingstone 1995:516-522.

Gene Therapy: Efficient Drug Development

The United States Food and Drug Administration (US FDA) defines gene therapy products as all products that mediate their effects by transcription and/or translation of transferred genetic material and/or by integrating into the host genome and that are administered as nucleic acids, viruses, or genetically engineered microorganisms. The products may be used to modify cells in vivo or transferred to cells ex vivo prior to administration to the recipient. In the United States, the development of gene therapies is regulated by the Office of Tissues and Advanced Therapies (OTAT) in the Center for Biologics Evaluation and Research (CBER), US FDA.

Most gene therapies are in development for the treatment of conditions or diseases that are serious and rare. The US FDA defines a serious condition as a disease or condition associated with morbidity that has substantial impact on day-to-day functioning. Whether a disease or condition is serious is matter of clinical judgment, based on its impact on such factors as survival, day-to-day functioning, or the likelihood that the disease, if left untreated, will progress from a less severe condition to a more serious one. The US FDA defines a rare disease as a disease that affects less than 200,000 people in the United States (i.e., disease prevalence is less than 200,000).

Over the last two decades, there have been important scientific advances that have facilitated the development of gene therapies. In 2017, three gene therapies received marketing approval in the United States. These three products are the first gene therapies approved by the US FDA, and represent the culmination of many years of scientific advances and maturation of the field of gene therapy.

Scientists, investigators, and regulators should now reassess the traditional approach to the development of these products. Particularly, in the setting of advancing science, there may be opportunities for more efficient drug development, particularly in the field of gene therapy.

This presentation will focus on steps to increase the efficiency of drug development for gene therapies.

Talking Points

1) In the United States, the development of gene therapies is regulated by the Office of Tissues and Advanced Therapies (OTAT), in the Center for Biologics Evaluation and Research (CBER), of the US Food and Drug Administration (US FDA).
2) Most gene therapies are being developed for the treatment of conditions that are serious and rare.
3) Scientific advances have facilitated the development of gene therapies.
4) In 2017, the US FDA approved its first three gene therapies.
5) Drug development of gene therapies should be more efficient.
6) Drug development is like baseball.

[GBC 1] KEYNOTE SPEECH & PLENARY SESSION

JUNGJIN SEO

Chairman of Celltrion Group

EDUCATION

- Bachelor of Science, Konkuk University (Seoul, Korea)
- Master of Science, Konkuk University (Seoul, Korea)
- Honorary Pharm.D., ChungBuk University (Cheongju, Korea)

EXPERIENCE

- Works as consultant for Korean Productivity Center
- Executive director at Daewoo Motor Company
- Founded Celltrion in 2002
- Set the groundwork for its technology, production facilities and finance operating as a CMO service provider for multinational pharmaceutical companies
- Succeed in developing the world's first mAb biosimilar 'Remsima' as well as oncology biosimilars

RECENT WORK

- Development of next-generation biologics such as antibody therapeutics, vaccines, and bio betters for infectious (viral) diseases
- Partnership agreements with a number of large global pharmaceutical companies including Pfizer, TEVA, establishing a mutually beneficial, win-win relationship with such partners

“Health for All - Changes Brought by mAb Biosimilar”

Everyone has the right to be healthy. But in reality, access to medical care is limited for some people, and there are many other factors in our life such as aging, budget pressure, and polarization. In these circumstances, the paradigm has been transformed in the pharmaceutical industry to provide more opportunities for patients.

In this change, Celltrion, for the first time in the world, has successfully developed biosimilars, which many people had claimed that it was impossible to do.

This success has a positive influence on the global biosimilar movement that even multinational pharmaceutical companies are getting more involved in the business. We would like to talk about what changes we have experienced in the global pharmaceutical market, and what roles Celltrion has to play so that we can make "health for all".

[GBC 1] KEYNOTE SPEECH & PLENARY SESSION

Annette Hicks

Senior Health Advisor, Watson Health, IBM

Annette is a Senior Health Advisor for IBM Watson Health and works internationally to support the Chief Health Officer, IBM Watson Health. Annette has experience in healthcare as a clinician as well as the ICT Industry which has created an appreciation for the potential of information technology and innovation in our healthcare industry. Her role sees her working with healthcare professionals, supporting the adoption of the newer technologies especially cognitive computing. Key part of the role is to work with clinicians and researchers to generate an evidence base on the impact of cognitive solutions within the clinical setting.

Annette is a member of the IBM Industry Academy which has a key focus to drive industry focused eminence of its members and across the industry collaboration to drive innovation.

She moved into her current role from a role that focused on supporting customers in health in IBM healthcare solutions as the Health Industry Leader Australia & New Zealand, since 2008.

Prior to joining IBM she has had senior roles in both the Health Industry and ICT in Australia. In Healthcare her clinical roles included General Nursing, Operating Room Management, Clinical Nurse Consultant and Assistant Director of Nursing
In the ICT industry she has experience in the areas of strategy, business development, solution development and sales, service delivery, product management and training.

Annette has a Bachelor in Health Administration, Bachelor of Science in Micro Biology & Bio Chemistry, Registered Nurse, Operating Room Management, as well as Masters in both Commercial Law & Business Administration.

The Future of Health with AI and Blockchain Technology

[GBC 1] KEYNOTE SPEECH & PLENARY SESSION

Ronald Piervincenzi

CEO, USP

PROFESSIONAL EXPERIENCE

US PHARMACOPEIAL CONVENTION, Inc. Rockville, MD
Chief Executive Officer Jan. 2014-present
• Provides strategic leadership for USP at the direction of its Board of Trustees
• Serves as Chair of the Council of Experts, USP's scientific standards-setting body

Biogen Idec, Inc. Cambridge, MA
VP, Development Sciences, Business Strategy July 2013-Jan. 2014
• Designed and launched Biogen's "Value-Based Medicine" function

McKinsey & Company, Inc. Summit, NJ
Principal (Partner) Oct. 2000-May 2013
• Selected non-client leadership roles within McKinsey:
– 2009-2011, Partner responsible/leader of McKinsey's global Pharmaceutical and Medical Products Research and Knowledge Network. Managed 40+ full-time professionals spanning locations in New Jersey, London, Brussels, and India including internal P&L, performance review and reporting, personnel appraisals and reviews, and promotions/terminations

USP Perspective in Biologics

Publicly available USP quality standards help ensure the purity, safety and benefits of medicines. USP standards also help ensure the integrity of medicines and their ingredients as they travel along global supply chains. For biologics, USP standards include monographs for individual products, general chapters that apply across multiple products, and reference standards. USP's collaborative standard-setting process is public and open to stakeholder participation from industry, academia, regulatory agencies, and other standard-setting organizations. This presentation will provide an overview of the role and use of public standards in protecting and promoting access to medicines, USP's approaches to development of reference standards, and updates on the USP approach for biologics.

[GBC 1] KEYNOTE SPEECH & PLENARY SESSION

Woongyang Park

Director, Samsung Medical Center

EDUCATION AND TRAINING

1982-1988	M.D. Seoul National University College of Medicine, Korea
1988-1995	Ph.D. (Biochemistry) Seoul National University Graduate School, Korea
1997-1998	Postdoctoral Fellow (Robert Darnell Lab) Rockefeller University, New York, USA

BRIEF CHRONOLOGY OF EMPLOYMENT

1988-1991	Research assistant, Dong-A University College of Medicine, Busan, Korea
1991-1996	Lecturer, Dong-A University College of Medicine, Busan, Korea
1998-2012	Professor, Seoul National University College of Medicine, Seoul, Korea
2013-present	Professor, Sungkyunkwan University School of Medicine, Suwon, Korea
2013-present	Director, Samsung Genome Institute, Samsung Medical Center, Seoul, Korea

PROFESSIONAL ACTIVITIES

2014-present	Editorial Board, Genome Biology (Springer)
2014-present	Editorial Board, Journal of Human Genetics (Nature Publishing Group)
2017-present	Committee member, National Science & Technology Council, Korea
2017-2018	Chairman, Healthcare Committee, Industry 4.0 Council, Korea

Precision Healthcare with Personal Genome Information

With the complete of human genome sequencing project, the advancement and cost reduction of DNA sequencing techniques enabled us to analyze individual genomes in research and clinical practice settings. Each individual has about four million variants in their genome, which could differentiate one from another. The set of sequence variations that an individual has represents the biological and medical characteristics of an individual, including disease. Our own genome sequence data could help us to find a way to become healthier. Screening for newborns is the best candidate for us to apply genome analysis. Genetic analysis is also needed to find genetic heterogeneity and rare variant in rare disease patients. We are trying to detect any actionable variants and information in patients' clinical specimens to determine the optimal treatment target, which will increase the efficiency of target cancer treatment and immunotherapy treatment in cancer patients. In addition, if the patient's clinical information and life-style information are integrated together, more accurate prevention, diagnosis and treatment are possible.

[GBC 1] KEYNOTE SPEECH & PLENARY SESSION

Murray Aitken
Executive Director, IQVIA

Murray Aitken is a senior vice president at IQVIA and the executive director of the IQVIA Institute for Human Data Science. Aitken is a renowned expert on critical healthcare issues around the world, including the role of medicine, the disruptive impact of technology, and the use of data science in improving decision-making and accelerating innovation.

Throughout his 15-year tenure at IMS Health and QuintilesIMS, Aitken served in various roles responsible for healthcare insights, corporate strategy, and consulting and services. Previously, he was a partner at McKinsey & Company and during his career was based in Los Angeles, Seoul and New Jersey offices, covering a broad range of industries, including life sciences and consumer goods.

He holds an MBA, with distinction, from Harvard University and Masters of Commerce from the University of Auckland in New Zealand.

Advancing the BioEconomy through Human Data Science

Progress in understanding human science, increased availability of human data, and advances in data science collectively have the potential to provide a new framework for advancing human health and the broader bioeconomy. Together, these capabilities form the foundation of Human Data Science and enable new levels of understanding of health and disease; faster translation of basic science to drug targets and mechanisms; more efficient development of new therapies and a reduction in the time for these to reach patients; more appropriate use of biopharmaceuticals based on predictive analytics and diagnostics; and greater ability to track the real-time impact of medicines on patient outcomes.

The appropriate application of Human Data Science can strengthen health systems and advance the bioeconomy – in Korea and beyond. It can empower and encourage innovation in all parts of the health system. All stakeholders and countries can contribute to this advancement, especially those with leadership in health data, digital health, and biological sciences.

This presentation will introduce the framework for Human Data Science and provide examples of how this can be applied across the bioeconomy, including in the emerging biopharma sector and as it relates to rare diseases. A call to action will focus on those accelerators of advancement that can enable Human Data Science to be fully leveraged by health systems and society, leading to improved human health for all.

[GBC 1] KEYNOTE SPEECH & PLENARY SESSION

Janmeet Anant
Senior Regulatory Consultant, Merck

Global Regulatory Affairs Manager with extensive experience with biopharmaceutical drug manufacturing process validation guidelines. As a technical manager, developed regulatory expertise by partnering with various biotherapeutic and diagnostic organizations. Demonstrated capability to drive business growth, based on over 15 years of commercial expertise in healthcare, comprising life sciences, biotechnology and pharmaceutical industries. Proven ability to lead a diverse team and deliver multiple strategic project results within quarterly timelines. Extensive project management skills were utilized to drive efficient results by partnering with R&D, sales, and product management.

PROFESSIONAL EXPERIENCE

EMD MILLIPORE CORPORATION, Bedford, MA	2009 – Present
Regulatory Advocate and Steward, Bioprocess Division	2012 – Present
Product Management, Bioprocess Division	2009 – 2012
GE HEALTHCARE, LIFE SCIENCES, Piscataway, NJ	1998 – 2009
Marketing Director, Healthcare Division, Life Sciences	1998 – 2009

MEMBERSHIPS:

- American Society of Mechanical Engineers – Bioprocess Engineering
- Parenteral Drug Association (PDA)
- Bioprocess Systems Alliance (BPSA), Executive Board Member
- International Society of Pharmaceutical Engineering (ISPE)
- American Society of Testing and Materials (ASTM)

EDUCATION

Ph.D. • Pharmacology • University of California, Los Angeles
Bachelor of Science • Chemistry • University of Oklahoma, Norman, OK

CERTIFICATION

Project Management Professional (PMP) Certification

Regulatory trends for innovation in biopharmaceutical manufacturing technologies

Biopharmaceutical manufacturing technology innovation has been stifled by perceived difficulty of complying with regulations rather than lack of science and engineering expertise. As a result, the industry has been dealing with issues like faltering product quality and regulatory compliance. The FDA has cited that increasing drug product recalls and shortages in the USA are based on quality issues, mainly with sterile injectable drug products. Another challenge for biologic drug products produced by cell culture is the manufacturing complexity, which is inherently more variable than a small-molecule drug made by chemical synthesis.

Recently, there have been several regulatory initiatives to help move the industry forward with manufacturing innovations that would improve drug product quality and potential reduce costs. The US FDA has a new commissioner who is driving a culture of innovation and reduced regulatory oversight. Implementation of single-use manufacturing, closed systems, and a move to continuous processing models has also been increasing efficiencies. For these, properly trained personnel is a challenge for many companies and greater regulatory engagement in emerging markets would be beneficial to ensure global alignment and approval. Some of these initiatives and industry trends will also help with manufacturing innovations for cell and gene therapeutic products, where are now in development. The involvement of Merck in supporting these biopharmaceuticals manufacturing regulatory trends will be covered.

[GBC 1] KEYNOTE SPEECH & PLENARY SESSION

Stefan Gluck
Vice President, Celgene Corporation

Stefan Glück, MD, PhD, is V.P of Global Medical Affairs, at Celgene Corporation since October 2014, and a medical oncologist with focus on breast cancer. He has overseen breast, ovarian, pancreatic and bladder cancer activities worldwide, as well as the Immuno-Oncology Program in solid tumors. Recently, his job requirements have shifted to include all solid tumors and most importantly Early Assets.

He previously served as a Sylvester Professor in the Department of Medicine at Miller School of Medicine, University of Miami, Florida until September 2014. From 2003–2008, he was the Clinical Director of the Braman Family Breast Cancer Institute, and from January 2009 - December 2010 Assistant Director of the Sylvester Comprehensive Cancer Center and Associate Chief, Division Hematology & Medical Oncology. He has been a PI of 37 clinical studies of breast cancer in Miami, as well as investigator in numerous scientific, translational projects.

Before his move to Miami, Dr. Glück was Director of Southern Alberta Breast Cancer Program at the Tom Baker Cancer Center, a Professor in the departments of oncology, medicine, pharmacology & therapeutics at the University of Calgary, Alberta, Canada, and Deputy Head, Dept. of Oncology at the University of Calgary.

He completed his medical studies at the Free University of West Berlin, Germany. The internship in Berlin was followed by residency in internal medicine and fellowship in hematology at the Heinrich Heine Universität in Düsseldorf, Germany, and a medical oncology & bone marrow transplant fellowship at the Princess Margaret Hospital, University of Toronto, Canada.

Dr. Glück was presented the "America's Top Oncologists" 2008 award from Consumers' Research Council of America, as well as "Best Doctors in America" honor since 2006, and has annually earned that prestige every year to 2014. This award was warranted after less than 3 years of working in the United States.

He is a member of such prestigious professional organizations, as the American Society of Clinical Oncology, European Society for Medical Oncology, American & European Association of Cancer Research, and the International Association for Breast Cancer Research. He is a reviewer of numerous journals e.g.: Journal of Clinical Oncology, European Journal of Cancer, Lancet Oncology, Lancet, Breast Cancer Research, The Oncologist, The Breast Journal, Clinical Breast Cancer and many others. He was Medical Associate Editor of Breast Cancer Research & Treatment and Co-Editor in Chief of Journal of Carcinogenesis and Clinical Communications Oncology that he co-founded in 2014. He has authored or co-authored over 270 articles. In addition, Dr Glück has written or co-written several book chapters and numerous journal abstracts, and has presented more than 380 papers at national and international meetings.

Successful planning and implementation for alliances: the winning strategy!

Talking points :
Regular triage meetings
Regular abstract screening
Regular F2F meetings with potential partners

Celgene is a global company with clear vision, values, behaviors and purpose: to change the course of human health through bold pursuits in science, and a promise to always put patients first. Through a joint effort of many departments, Celgene invests a substantial amount of revenues to research. Tactical alliances with universities, cancer centers, biotech and pharma companies further strengthen its role. With the help of advisory boards, engaging key opinion leaders in science and clinic, the road to reach the goals becomes easier and relevant.